IL288176A - Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer - Google Patents
Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancerInfo
- Publication number
- IL288176A IL288176A IL288176A IL28817621A IL288176A IL 288176 A IL288176 A IL 288176A IL 288176 A IL288176 A IL 288176A IL 28817621 A IL28817621 A IL 28817621A IL 288176 A IL288176 A IL 288176A
- Authority
- IL
- Israel
- Prior art keywords
- naphthoquinone
- complexes
- cancer therapy
- functional gold
- gold carbene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/10—Silver compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851187P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/034415 WO2020237225A1 (en) | 2019-05-22 | 2020-05-22 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288176A true IL288176A (en) | 2022-01-01 |
Family
ID=73459479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288176A IL288176A (en) | 2019-05-22 | 2021-11-16 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12577262B2 (enExample) |
| EP (1) | EP3972981A4 (enExample) |
| JP (1) | JP2022532801A (enExample) |
| KR (1) | KR20220024123A (enExample) |
| CN (1) | CN114174305A (enExample) |
| AU (1) | AU2020279478A1 (enExample) |
| CA (1) | CA3140716A1 (enExample) |
| IL (1) | IL288176A (enExample) |
| MX (1) | MX2021014195A (enExample) |
| SG (1) | SG11202112856QA (enExample) |
| WO (1) | WO2020237225A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003483D0 (en) | 2010-03-02 | 2010-04-14 | Univ St Andrews | Gold complexes |
| US8900654B2 (en) | 2011-07-29 | 2014-12-02 | Thin Film Electronics, Inc. | Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds |
| PL2814829T3 (pl) | 2012-02-13 | 2017-06-30 | Bristol-Myers Squibb Company | Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania |
| WO2017083595A1 (en) | 2015-11-10 | 2017-05-18 | Massachusetts Institute Of Technology | Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods |
| WO2019006327A1 (en) * | 2017-06-30 | 2019-01-03 | Board Of Regents, The University Of Texas System | OR-CARBENE COMPLEXES CONTAINING NAPHTOQUINONE AND METHODS OF USE |
-
2020
- 2020-05-22 WO PCT/US2020/034415 patent/WO2020237225A1/en not_active Ceased
- 2020-05-22 JP JP2021569297A patent/JP2022532801A/ja active Pending
- 2020-05-22 US US17/595,670 patent/US12577262B2/en active Active
- 2020-05-22 SG SG11202112856QA patent/SG11202112856QA/en unknown
- 2020-05-22 AU AU2020279478A patent/AU2020279478A1/en not_active Abandoned
- 2020-05-22 CA CA3140716A patent/CA3140716A1/en active Pending
- 2020-05-22 MX MX2021014195A patent/MX2021014195A/es unknown
- 2020-05-22 KR KR1020217041752A patent/KR20220024123A/ko not_active Ceased
- 2020-05-22 CN CN202080050300.4A patent/CN114174305A/zh active Pending
- 2020-05-22 EP EP20809519.0A patent/EP3972981A4/en not_active Withdrawn
-
2021
- 2021-11-16 IL IL288176A patent/IL288176A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112856QA (en) | 2021-12-30 |
| CA3140716A1 (en) | 2020-11-26 |
| US12577262B2 (en) | 2026-03-17 |
| CN114174305A (zh) | 2022-03-11 |
| EP3972981A4 (en) | 2023-05-24 |
| EP3972981A1 (en) | 2022-03-30 |
| KR20220024123A (ko) | 2022-03-03 |
| MX2021014195A (es) | 2022-02-21 |
| JP2022532801A (ja) | 2022-07-19 |
| US20220340601A1 (en) | 2022-10-27 |
| AU2020279478A1 (en) | 2021-12-09 |
| WO2020237225A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282663A (en) | Bt1718 for use in treating cancer | |
| IL288485A (en) | Anti-trop2 antibody-drug conjugates for use in treating cancer | |
| PL2958945T3 (pl) | Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| IL264598A (en) | Antibody-protein nanoparticle complexes adapted for cancer therapy | |
| HUE063145T2 (hu) | Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra | |
| EP3548088A4 (en) | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITÉCAN (IMMU-132) | |
| IL258828A (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| DK3624837T3 (da) | Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling | |
| PL3806898T3 (pl) | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu | |
| IL277421B (en) | Flagellin polypeptide from Enterococcus genus for use in cancer treatment | |
| IL280510A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
| IL289787A (en) | Antibody combinations for treatment of cancer in specific patients | |
| EP3581182A4 (en) | DRUG COMBINATION FOR THE TREATMENT OF PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
| HUE059448T2 (hu) | Liposzómás készítmény, rák kezelésében való alkalmazásra | |
| IL282093A (en) | Combination therapy for cancer | |
| EP4424323A3 (en) | Anti-folr1 immunoconjugate dosing regimens | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| IL291170A (en) | Treatment of hr deficient cancer | |
| ZA202005847B (en) | Cancer therapy | |
| IL282294A (en) | Combinations for immune-modulation in cancer treatment | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL281600A (en) | Methods of treating cancer | |
| IL319432A (en) | Methods of treating cancer | |
| HRP20182041T1 (hr) | Pripravci oksprenolola za liječenje raka | |
| IL282313A (en) | Abituzumab for the treatment of colorectal cancer |